Vijay Pande Shares Valuable Investment Insights from His $4 Billion Experience at a16z

Vijay Pande established his academic reputation before transitioning to the investment sector nearly a decade ago. This change was spurred by Marc Andreessen and Ben Horowitz, who, despite their initial reservations regarding healthcare and life sciences investments, decided to explore this field by appointing Pande as their leader. At the time, he was an esteemed chemistry professor at Stanford, recognized for creating Folding@home, a distributed computing initiative that utilized countless personal computers for supercomputing tasks aimed at disease research. Over the next ten years, he substantially enhanced a16z’s investment capabilities, managing close to $4 billion.

In June of the previous year, Pande opted to step back from his extensive role and create a more focused venture. His new firm, VZVC, co-founded with experienced investor Zach Werner, concentrates on making a limited number of strategic investments annually, rather than diluting resources across many projects. The company operates with a lean team and creatively incorporates AI into its functions.

To gain insight into Pande’s extraordinary transition, we discussed his decision to concentrate on fewer investments in light of current market trends. We also addressed a significant challenge in AI-driven biotechnology: the obstacles in accessing biological data online, which results in fragmented datasets. What implications does this have for future medical advancements, and who will benefit?

This dialogue has been summarized for clarity. You can listen to the complete discussion below.

You mentioned that biology is shifting from a “science of discovery” to an engineering discipline. What does that entail?

Traditionally, drug development has been fraught with uncertainties. The significant transformation occurring now is that AI and machine learning can analyze intricate data to identify drug targets for particular diseases, streamline the drug development process, and even enhance clinical trials—the most expensive phase of the development process.

I’ve heard that the costs of clinical trials are decreasing, thanks to synthetic data reducing the reliance on participants.

That’s an optimistic perspective. While the initial costs and timelines of clinical trials have indeed decreased, primarily due to AI, the overall expenditure for conducting a trial can still reach hundreds of millions, adding to the high costs tied to new therapies. The likelihood of a drug moving from early trials to phase three is about 20%. With 80% of trials failing—and each failure accruing significant costs—expenses can rise rapidly. Most failures arise not from errors by biologists but from testing drugs on animal models like mice, which often fail to replicate human responses accurately. Although AI models are not infallible, they generally perform better than animal models, opening up promising avenues.

[The next question is]: Is this drug the right one for me?

You’re referring to personalized medicine…

What you actually seek is precision medicine. When patients present doctors with complicated issues, physicians are often left making educated guesses due to insufficient data. They might prescribe one treatment, and if it doesn’t work, they try another, repeating the cycle. This is particularly common in cancer therapies. Ideally, the first drug given should be the correct one. Currently, blood test results are compared to averages from the general population, but they should be tailored to reflect each patient’s unique profile. We are gradually improving our knowledge of the most effective treatments for individual patients.

Do you think this progress has been steady, or has it accelerated recently?

I believe this transformation has been influenced by several interconnected factors. For a long time, precision medicine focused heavily on genomics. However, the human genome serves as a starting point for ongoing advancements. Today, various measurable elements, including proteomics, are providing deeper insights into health conditions and diseases. Additionally, innovations in robotics and automation, closely tied to AI, are fostering productive synergies.

Over the past decade, we’ve observed consistent growth in the integration of AI within biology and chemistry. The biological angle aims to address diseases, while the chemical perspective focuses on developing drugs for specific proteins. Indeed, meaningful strides have been made in this field.

You mentioned that biology is one area where data accessibility online remains limited. What effect does this have on industry growth?

This indicates a deficiency of shared datasets that organizations could collaboratively utilize to train their models. This gap presents distinct challenges from an AI standpoint.

Doesn’t this highlight a persistent issue in medicine, where professionals often operate in competitive silos?

You’ve pinpointed a significant concern. When a patient is diagnosed with a cancer type that overlaps both oncology and endocrinology, specialists in these areas often struggle to collaborate effectively. AI holds great promise here, as it can integrate knowledge from various fields, mirroring the collaborative efforts of top doctors.

Is there adequate data sharing to actualize this vision? I gather that founders and investors can be protective of their innovations…

I’m observing a growing trend toward creating comprehensive biological information atlases, often designed as foundational models. As these initiatives gain traction, I expect developments comparable to those we’ve witnessed with open-source large language models outpacing corporate alternatives: open-source foundational models in biology will have significant impacts.

You have connections to Genesis Therapeutics, which began in your Stanford lab, and Insitro, founded by your former colleague Daphne Koller. Additionally, you are collaborating with a founder you’ve known for two decades. What qualities do you value in founders, and which sectors are you focused on?

My focus revolves around two main areas: AI for healthcare delivery, a field I extensively studied at a16z, and AI’s application in clinical trials.

Trust is essential for me when evaluating founders. I seek partners with integrity—individuals who fulfill their commitments. My goal is to foster relationships that last for five to ten years, ideally supporting them as they embark on their next entrepreneurial journeys. I prefer collaborators who perceive success as a shared endeavor rather than a competitive race.

What successes and challenges have you encountered during your investment journey so far?

When I first started discussing AI and machine learning applications in medicine over a decade ago, skepticism was widespread, with many doubting their relevance and feasibility. It has been gratifying to observe a shift in these attitudes.

I have learned that, regardless of how promising new technologies may seem, a solid market strategy is essential. I frequently advise my founders—especially those with scientific or product-focused backgrounds—to channel their creativity and intelligence into market strategies, as navigating the go-to-market landscape can be just as daunting, if not more so, than the technology itself.

Can you elaborate on how you are structuring this new company differently from your role at a16z?

We are applying a distinctly different strategy now… VZ represents the initials of my name, Vijay, and my co-founder Zach Werner—he is the “Z.” We intentionally keep our team small… for investments, it’s just the two of us. While we initially considered adding associates, our current structure has made that unnecessary.

How do you define “concentrated” in your investment strategy?

We aren’t targeting 30 investments each year… rather, we aim for around five concentrated investments. Bringing a new company into our portfolio feels akin to welcoming a new child into a family—it comes with significant responsibility.

Given this structure, who do you compete with for deals?

Interestingly, with this strategy, we often find ourselves not competing for the popular rounds—investors generally appreciate our involvement. This contrasts sharply with the usual rush for Series A or B investments. Often, investors value our engagement because of our hands-on approach and the unique contributions Zach and I provide. I hold great respect for individuals like Antonio Gracias at Valor for his consistent contributions, and I draw inspiration from Thrive’s success with a more focused portfolio as well. Naturally, my experiences at a16z continue to shape my perspective, but these additional examples have expanded my understanding.

What aspects of AI and biotechnology do you think are currently overstated?

The reality is, AI can unveil insights that exceed human capabilities. The problem arises when claims are made that AI can resolve all issues. The hesitation doesn’t arise from skepticism towards AI, but rather from apprehensions about data quality. Large language models excel when provided with extensive training datasets. When critical data is lacking, AI cannot simply substitute for that absence.

When you make purchases through links in our articles, we may receive a small commission. This does not influence our editorial independence.